

Correlation Between Toxin-Antitoxin Systems and Persistence States in *Staphylococcus aureus* Isolates

Faed Osama Fahdil¹ , Laith B. Alhusseini¹  

¹ Department of Ecology, College of Science, Kufa University, Kufa, Najaf, Iraq

Article Info

Article type:
Review article

Article History:

Received: Mar. 14, 2024
Received: Apr. 11, 2024
Accepted: May. 15, 2024
Published Online: Sep. 22, 2024

✉ Correspondence to:

Laith B. Alhusseini
Department of Ecology, College
of Science, Kufa University,
Kufa, Najaf, Iraq

Email:

laithphd100@gmail.com

ABSTRACT

Introduction: Levels of the human epidermal growth factor receptor 2 (HER2) gene are low in normal breast tissue, but half of the patients with breast cancer exhibit higher levels of this receptor. The differential expression of the HER2 gene in normal and malignant cells makes it an excellent biomarker for therapeutic purposes. In this study, we evaluated the degree of HER2 overexpression in patients and its relationship with age and the occurrence of metastases.

Materials & Methods: In this retrospective, registry-based, two-center cohort study, information on 1500 breast cancer patients recruited from Shahid Mostafa Khomeini Hospital in Ilam Province was collected from 2020 to 2023.

Results: The likelihood of metastasis in cancer patients with HER2 gene expression was three times higher (adjusted OR: 2.82; 95% CI: 1.79–3.29; P=0.001). Additionally, the involvement of lymph nodes (adjusted OR: 2.01; 95% CI: 0.87–3.79; P=0.03) was significantly associated with increased metastasis.

Conclusion: This study demonstrates that HER2 gene expression and the number of involved lymph nodes are significant prognostic factors that increase the risk of metastasis. Therefore, implementing comprehensive breast cancer screenings can play an important role in the treatment and prevention of metastasis in breast cancer patients.

Keywords: Toxin-antitoxin systems, Persister Cells, Recalcitrance, Tolerant, Physiology

➤ How to cite this paper

Faed Osama Fahdil, Laith B. Alhusseini. Correlation Between Toxin-Antitoxin Systems and Persistence States in *Staphylococcus aureus* Isolates. J Bas Res Med Sci. 2024; 11(4):68-75.

Introduction

Staphylococcus aureus causes a large number of nosocomial and community-acquired illnesses. It causes a variety of diseases, ranging from deadly systemic disorders to localized skin infections (1). Several investigations have demonstrated that *S. aureus* may live an intracellular existence, thriving inside osteoblasts and osteocytes found in human bone cells mostly in the *S. aureus* SCV state (2), but this is also likely to be the case in its L-form cell state. *S. aureus* can live inside these host cells for an extended period without being noticed; it has been demonstrated that these bacteria have a malfunctioning host recognition mechanism (3).

This allows the bacteria to survive for a long time in the environment of bone cells and serves as a reservoir for more infections that may recur. It is widely accepted that microbes use survival mechanisms to deal with outside stimuli (4). One of the most prevalent microbial stress reactions to environmental stressors, such as oxidative stress, temperature changes, food shortages, and high osmolarity, is a viable but nonculturable (VBNC) condition (5). A unique physiological state known as a VBNC state occurs when bacteria fail to grow on a medium but continue carrying out certain metabolic processes (6). However, in a high concentration of antibiotics, some *S. aureus* subpopulations would alter their metabolic process, enter the dormancy state, and become persistent (7). Many studies suggested the implication of Toxin-antitoxins (TAS) in the formation of persistent cells (8). TAS modules, which comprise a toxin and its antitoxin equivalent, are ubiquitous gene loci identified in bacteria. Antitoxin reduces the toxicity of toxins under normal physiological conditions; however, under stress, TA modules are crucial to the physiology of bacteria because they help with post-segregational death, abortive infection, biofilm formation, and persister cell development. While other intracellular molecular targets have also been reported, most toxins are proteinaceous and impact translation or DNA replication. Conversely, antitoxins can be either

proteins or RNAs that, through direct interaction or with the aid of other signalling elements, neutralize their cognate toxin and aid in the regulation of the TA module (8). Nearly every species of bacteria has TAS (9). They can range from being absent in certain bacteria to being quite common in others (10). They can be located on plasmids or chromosomes (11). For specifics on TAS system types I through VI (12). Typically, a TAS codes for a stable toxic ingredient and its unstable antidote, or antitoxin, which can be a protein or RNA that, under normal growth conditions, inactivates the harmful action. Lower antidote concentrations are the outcome of stress conditions, and higher toxin activity is caused by an imbalance between toxin and antitoxin (8). An antitoxin works through various mechanisms to stop its cognate toxin from being toxic under optimal development conditions. However, it is either downregulated or quickly broken down by intracellular proteases in response to stress or plasmid loss (13). According to the type of antitoxin and the way the toxin and antitoxin interact to produce their effects, TAS is categorized into six types (13). In summary, the components of type I TAS are non-coding antisense RNA antitoxin, which binds to the mRNA of the toxin to either inhibit its translation into proteins or promote its mRNA degradation (14). The production of toxin mRNA and, in most cases, small membrane-associated pore-forming toxin peptides, also known as cytosolic nucleases, occurs when the labile antitoxin short RNA (sRNA) is broken down. Toxins and antitoxins are both proteins in Type II systems. Since most type II toxins are endoribonucleases, antitoxins feature two domains: one for binding DNA and the other for binding toxins, which inhibits the activity of the toxin (15). Proteolysis breaks down antitoxins under different stress circumstances, releasing the toxins to prevent translation and replication. RNA is the antitoxin type III, just as in type I. The toxin nuclease breaks down the antitoxin precursor mRNA into antitoxin sRNAs, which then bind to the toxin directly to neutralize its active site and create pseudoknots (16). Both components of type IV are proteins, but they do not

interact. The antitoxin counteracts the toxin action by binding and maintaining cytoskeletal filament bundling, whereas the toxin component prevents cytoskeletal proteins from polymerizing to inhibit cell division (17,18). There has only been one description of Type V and VI TAS. The *ghoT* toxin mRNA in Type V TAS is degraded by the RNase antitoxin *GhoS*. A TAS being governed by another TAS is a unique instance. *SocB* toxin and *SocA* antitoxin are both proteins found in Type VI (12). As of right now, *S. aureus* has been reported to harbor type I *SprA1-SprA1AS* and *SprF1-SprG1*, type II *MazEF*, *YefMSa1-YoeBSa1*, *YefMSa2-YoeBSa2*, and *PemIK* TAS (19). The molecular and biological processes of TAS are being extensively studied because they may provide solutions to common clinical issues such as biofilm-forming infections, pathogenicity, antibiotic resistance, and persistence. However, many of the discovered TAS still have unknown biological roles (20). Further research is still required to advance our knowledge of TAS in Gram-positive bacteria, as the majority of TAS research has been conducted in Gram-negative bacteria (21). The goal of this review is to outline and talk about what is currently known about *S. aureus* TAS.

Persistence of Staphylococcus aureus Infection

Staphylococcus aureus can change into the small-colony variant (SCV) phenotype to live inside host cells. Small colony variations (SCVs) are bacterial variants of *S. aureus* that arise from changes in metabolic genes, leading to the formation of auxotrophic bacterial subpopulations (22). Dormancy, which is defined here as a state in which cells are not engaged in any metabolic activity, is the cause of these persister cells. In 1942, *S. aureus* was used to characterize this trait for the first time and discovered that penicillin did not kill one in a million *S. aureus* cells and that the surviving cells did not undergo any genetic changes. As a result, these cells should not be regarded as resistant but rather as

phenotypic varieties that are tolerant to antibiotics (23).

Persistent infections, either recurrent or chronic, develop in tandem with the appearance of SCVs. This slow-growing *S. aureus* subpopulation exhibits a changeable phenotype (stable or unstable), is produced in the host cells, has a non-homogeneous genetic background, and produces tiny colonies on solid-medium agar. The stable SCVs recovered from clinical specimens have been found to carry particular alterations in metabolic pathways, even though almost all SCVs separated from clinical specimens can quickly grow back to their parental condition (24). Certain *S. aureus* subpopulations do not respond to antibiotics, making bacterial removal inefficient. Through changes in its genetic composition, *S. aureus* can develop resistance to antibiotics, and genetic investigations have uncovered a significant percentage of the mechanisms driving the emergence of these antibiotic-resistant species. Persister cells are another subpopulation that is resistant to antibiotics. Growing clinical data indicate that these persister cells play a significant role in antibiotic resistance and persistent infection; nevertheless, a thorough understanding of the mechanisms underlying the development of *S. aureus* persister cells is lacking (25). Bacterial persister cells are known as phenotypic variations that display antibiotic tolerance and a temporary non-growing condition. According to studies, bacteria that survive antibiotic treatment inside host cells are persister cells. They exhibit biphasic death and, when monitored at the single-cell level, eventually achieve a uniformly non-responsive, non-dividing condition. After the antibiotics are stopped, this phenotype is stable yet reversible. While still metabolically active, intracellular *S. aureus* persister cells exhibit a changed transcriptome profile that is in line with the activation of stress responses, such as heat shock, cell wall stress, SOS pathway (an inducible DNA damage repair system), and stringent response (26).

Importance of Defining Persistence in the Study of Persisters

One subset of bacteria has an epigenetic characteristic known as the persistence phenotype, characterized by slow growth and resistance to antibiotic treatment. The phenotype is obtained through an impulsive, reversible transition between persister and normal cells (Figure 1). These data show that persister cells, whose sluggish rate of division during growth results in lower population

fitness, may be used by clonal bacterial populations as a kind of "insurance policy" against drug interactions (27). Persister cells, by definition, can withstand extended exposure to antibiotics before returning to a sensitive, actively developing phenotype in the absence of environmental stress, which underscores their importance. Persister cells that tolerate antimicrobial therapy may serve as a breeding ground for mutants resistant to antibiotics (28).




Figure 1. Progression of Persister Cell Formation During Antibiotic Treatment (7)

Pathogenesis of *Staphylococcus aureus* Associated with Persister Formation

Based on the proteome and metabolites observed during the development of *S. aureus* persister cells exposed to vancomycin and enrofloxacin, the research provided dynamic insights into the molecular physiology of persister cell formation following exposure to two different antibiotics with different mechanisms of action. The information reveals that while cells that are phenotypically categorized as persister cells share a number of molecular traits, they also significantly differ in a large number of other molecular characteristics. These differences shed light on eliminating persister cells, which has important therapeutic implications (29). Another study used CRISPR-dCas9 to knock down *tcaA*, *tcaB*, and *tcaR*. The results demonstrated

that while *tcaB* suppression did not result in persistence, a notable increase in persister cells was observed when *tcaA* was suppressed by dCas9. The results were further investigated by producing a *tcaA* mutant, which demonstrated *tcaA* created a large increase in persister cells in contrast to the wild type. It was concluded that the gene *tcaA* enhances persister cells and glycopeptide resistance in *S. aureus* and may be a possible target for therapy (30). In many bacterial species, PhoU homologs play a vital role in the control of persister cells production and phosphate metabolism; however, the specific features of their roles vary depending on the species. The development of persister cells and virulence factors are tightly linked to the pathogenesis of *S. aureus*. It is still unknown what two PhoU homologs in *S. aureus*, PhoU1 and PhoU2 (31).

Toxin-Antitoxin Modules That Affect the Proportion of Staphylococcus aureus Persisters

Most prokaryotes have tiny genetic components called toxin-antitoxin (TA) systems. They are countered by antitoxins and encode toxin proteins that impede essential cellular activities (32). The TA types I, II, and III genes have been found in *S. aureus*. A sequence-specific RNase called MazF, the toxin of the mazEF locus, cleaves several transcripts, including those encoding pathogenicity factors. Two distinct, but auto-regulated TA systems that result in ribosome-dependent RNases are represented by two yefM-yoeB paralogs (19)

Furthermore, a tripartite TA system consisting of omega, epsilon, and beta contributes to the stability

of resistance factors (19). RNA antitoxins post-transcriptionally regulate the SprA1/SprA1AS and SprF1/SprG1 systems, which encode tiny membrane-damaging proteins (figure 2). Although they have not yet been validated experimentally, TA systems in *S. aureus* that are regulated by the interaction between toxin protein and antitoxin RNA have been discovered in silico (33). If these genetic loci are druggable targets, a deeper examination of potential connections between TA systems and *S. aureus* pathophysiology will clarify this (20,34). The conversion of a cyclopeptide antibiotic from a staphylococcal TA toxin emphasizes the promise of TA systems as relatively unexplored sources of drug development (19).




Figure 2. *Staphylococcus aureus* Toxin-Antitoxin Systems (19).

Regulation of Toxin and Antitoxin Modules in Promoting Staphylococcus aureus Persisters Formation

The development of persister cells has been connected to toxin-antitoxin systems; nonetheless, the molecular pathways underlying bacterial persistence remain mostly unclear. Schuster et al. demonstrate how the important human pathogen *S. aureus* binds to translating ribosomes of SprF1, a type I antitoxin, reducing the pathogen's total protein synthesis during growth. Because of its increased

stability under hyperosmotic stress, SprF1 levels rise, collect on polysomes, and reduce protein production (19). Through the use of an internal 6-nucleotide sequence on its 5' end, SprF1 binds to ribosomes and inhibits initiator transfer RNA binding, hence reducing translation initiation. The ribosome-bound antitoxin is displaced by an excess of messenger RNA, which permits the ribosomes to go through extra translation cycles even though this RNA antitoxin can also displace ribosome-bound mRNA (35).

This translation-attenuation mechanism encourages antibiotic persister cell production, which is mediated by an RNA antitoxin. With its dual role of repressing toxin expression via its 3'-end and fine-tuning total bacterial translation via its 5'-end, the untranslated SprF1 is a dual-function RNA antitoxin. SprF1 also interacts with a fraction of polysomes and ribosomes that may facilitate the creation of antibiotic persister cells and translation retardation, owing to a purine-

rich region at its 5' terminus (figure 3). Type II toxins target bacterial translation, but not type I toxins³. The situation is different in our case because the RNA antitoxin, rather than the toxin, binds to a subset of translating ribosomes. In bacteria, two ribosome-associated regulatory RNAs (ribosome-associated non-coding RNAs) were identified: signal-recognition particle RNA²⁷ and transfer-messenger RNA 26 (35,36).




Figure 3. In *S. aureus*, the RNA antitoxin SprF1 binds to ribosomes to inhibit translation, promoting the formation of persister cells (35).

Conclusion

As outlined here, a small portion of the population develops into persister cells making it difficult to treatment. The increasingly evident that the TA systems play a role in bacterial activity and are more than just genetic debris. Therefore, TA systems could serve as targets for the development of anti-persistence model in *S. aureus*.

Acknowledgements

We thank the members of Department of Ecology, College Science, Kufa University.

Financial support

This research did not receive any grant funding.

Conflict of interest

The authors report no conflict of interest in this study.

Authors' contributions

FAF, and LBA: conceptualization. FAF, and LBA: investigation and writing—original draft preparation. All authors have read and agreed to the published version of the manuscript.

References

1. Lee AS, De Lencastre H, Garau J, Kluytmans J, Malhotra-Kumar S, Peschel A, et al. Methicillin-resistant *Staphylococcus aureus*. *Nat Rev Dis Prim*. 2018;4(1):1–23.
2. Urish KL, Cassat JE. *Staphylococcus aureus* Osteomyelitis: Bone, Bugs, and Surgery. *Infect Immun*. 2020 Jun;88(7).
3. Yang D, Wijenayaka AR, Solomon LB, Pederson SM, Findlay DM, Kidd SP, et al. Novel Insights into *Staphylococcus aureus* Deep Bone Infections: the Involvement of Osteocytes. *MBio*. 2018 Apr;9(2).
4. Wu D, Forghani F, Daliri EB-M, Li J, Liao X, Liu D, et al. Microbial response to some nonthermal physical technologies. *Trends Food Sci Technol*. 2020;95:107–17.
5. Zhao X, Zhong J, Wei C, Lin C-W, Ding T. Current perspectives on viable but non-culturable state in foodborne pathogens. *Front Microbiol*. 2017;8:237514.
6. Zhao F, Bi X, Hao Y, Liao X. Induction of viable but nonculturable *Escherichia coli* O157: H7 by high pressure CO₂ and its characteristics. *PLoS One*. 2013;8(4):e62388.
7. Renbarger TL, Baker JM, Sattley WM. Slow and steady wins the race: an examination of bacterial persistence. *AIMS Microbiol*. 2017;3(2):171–85.
8. Singh G, Yadav M, Ghosh C, Rathore JS. Bacterial toxin-antitoxin modules: classification, functions, and association with persistence. *Curr Res Microb Sci*. 2021 Dec;2:100047.
9. Alhusseini LB, Maleki A, Kouhsari E, Ghafourian S, Mahmoudi M, Al Marjani MF. Evaluation of type II toxin-antitoxin systems, antibiotic resistance, and biofilm production in clinical MDR *Pseudomonas aeruginosa* isolates in Iraq. *Gene Reports*. 2019;17.
10. Ramage HR, Connolly LE, Cox JS. Comprehensive functional analysis of *Mycobacterium tuberculosis* toxin-antitoxin systems: implications for pathogenesis, stress responses, and evolution. *PLoS Genet*. 2009 Dec;5(12):e1000767.
11. Hayes CS, Sauer RT. Toxin-antitoxin pairs in bacteria: killers or stress regulators? *Cell*. 2003 Jan;112(1):2–4.
12. Wang X, Lord DM, Cheng H-Y, Osbourne DO, Hong SH, Sanchez-Torres V, et al. A new type V toxin-antitoxin system where mRNA for toxin GhoT is cleaved by antitoxin GhoS. *Nat Chem Biol*. 2012 Oct;8(10):855–61.
13. Unterholzner SJ, Poppenberger B, Rozhon W. Toxin-antitoxin systems: biology, identification, and application. *Mob Genet Elements*. 2013;3(5):e26219.
14. Wen J, Fozo EM. sRNA antitoxins: more than one way to repress a toxin. *Toxins (Basel)*. 2014;6(8):2310–35.
15. Afif H, Allali N, Couturier M, Van Melder L. The ratio between CcdA and CcdB modulates the transcriptional repression of the ccd poison-antidote system. *Mol Microbiol*. 2001 Jul;41(1):73–82.
16. Fineran PC, Blower TR, Foulds IJ, Humphreys DP, Lilley KS, Salmond GPC. The phage abortive infection system, ToxIN, functions as a protein-RNA toxin-antitoxin pair. *Proc Natl Acad Sci*. 2009;106(3):894–9.
17. Masuda H, Tan Q, Awano N, Wu K-P, Inouye M. YeeU enhances the bundling of cytoskeletal polymers of MreB and FtsZ, antagonizing the CbtA (YeeV) toxicity in *Escherichia coli*. *Mol Microbiol*. 2012 Jun;84(5):979–89.
18. Brown JM, Shaw KJ. A novel family of *Escherichia coli* toxin-antitoxin gene pairs. *J Bacteriol*. 2003 Nov;185(22):6600–8.
19. Schuster CF, Bertram R. Toxin-Antitoxin Systems of *Staphylococcus aureus*. *Toxins (Basel)*. 2016 May;8(5).
20. Harms A, Brodersen DE, Mitarai N, Gerdes K. Toxins, Targets, and Triggers: An Overview of Toxin-Antitoxin Biology. *Mol Cell*. 2018 Jun;70(5):768–84.
21. Fisher RA, Gollan B, Helaine S. Persistent bacterial infections and persister cells. *Nat Rev Microbiol*. 2017 Aug;15(8):453–64.
22. Melter O, Radojević B. Small colony variants of *Staphylococcus aureus*. *Folia Microbiol (Praha)*. 2010;55:548–58.
23. Hobby GL, Meyer K, Chaffee E. Observations on the Mechanism of Action of Penicillin. *Proc Soc Exp Biol Med*. 1942;50(2):281–5.
24. Tuchscher L, Löffler B, Proctor RA. Persistence of *Staphylococcus aureus*: Multiple Metabolic Pathways Impact the Expression of Virulence Factors in Small-Colony Variants (SCVs). *Front Microbiol*. 2020;11:1028.
25. Chang J, Lee R-E, Lee W. A pursuit of *Staphylococcus aureus* continues: a role of persister cells. *Arch Pharm Res*. 2020 Jun;43(6):630–8.
26. Peyrusson F, Varet H, Nguyen TK, Legendre R, Sismeiro O, Coppée J-Y, et al. Intracellular *Staphylococcus aureus* persists upon antibiotic exposure. *Nat Commun*. 2020 May;11(1):2200.
27. Kussell E, Kishony R, Balaban NQ, Leibler S. Bacterial persistence: a model of survival in changing environments. *Genetics*. 2005 Apr;169(4):1807–14.
28. Hurlow JJ, Humphreys GJ, Bowling FL, McBain AJ. Diabetic foot infection: A critical complication. *Int Wound J*. 2018 Oct;15(5):814–21.
29. Liu S, Huang Y, Jensen S, Laman P, Kramer G, Zaat SAJ, et al. Molecular physiological characterization of the dynamics of persister formation in *Staphylococcus aureus*. *Antimicrob Agents Chemother*. 2024 Jan;68(1):e0085023.
30. Wei W, Chen Z-N, Wang K. CRISPR/Cas9: A Powerful Strategy to Improve CAR-T Cell Persistence. *Int J Mol Sci*. 2023 Aug;24(15).
31. Shang Y, Wang X, Chen Z, Lyu Z, Lin Z, Zheng J, et al. *Staphylococcus aureus* PhoU Homologs Regulate Persister Formation and Virulence. *Front Microbiol*. 2020;11:865.

32. Akarsu H, Bordes P, Mansour M, Bigot D-J, Genevoux P, Falquet L. TASmania: a bacterial toxin-antitoxin systems database. PLoS Comput Biol. 2019;15(4):e1006946.
33. Pichon C, Felden B. Small RNA genes expressed from *Staphylococcus aureus* genomic and pathogenicity islands with specific expression among pathogenic strains. Proc Natl Acad Sci U S A. 2005 Oct;102(40):14249–54.
34. Grady R, Hayes F. Axe-Txe, a broad-spectrum proteic toxin-antitoxin system specified by a multidrug-resistant, clinical isolate of *Enterococcus faecium*. Mol Microbiol. 2003 Mar;47(5):1419–32.
35. Otto G. An arresting antitoxin. Nat Rev Microbiol. 2021;19(3):138–9.
36. Felden B, Augagneur Y. Diversity and Versatility in Small RNA-Mediated Regulation in Bacterial Pathogens. Vol. 12, Frontiers in Microbiology . 2021.